Simcere Pharmaceutical Group Limited

2096

HK0000658531

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 01:38:30 12/01/2026 pm IST			5-day change	1st Jan Change
11.53 ^HKD	-5.10%		-3.27%	-3.68%

09:35am	Simcere Pharmaceutical to Spin Off, List Chinese Subsidiary; Shares Down 7%	MT
09/01	Simcere Pharmaceutical announces spin-off & separate listing of Simcere Zaiming Pharmaceutical	RE

Certain Orinary Shares of Simcere Pharmaceutical Group Limited are subject to a Lock-Up Agreement Ending on 9-DEC-2025.

Published on 12/09/2025 at 05:55 am IST

S&P Capital IQ

Simcere Pharmaceutical Group Limited

-5.10%

Certain Orinary Shares of Simcere Pharmaceutical Group Limited are subject to a Lock-Up Agreement Ending on 9-DEC-2025. These Orinary Shares will be under lockup for 90 days starting from 10-SEP-2025 to 9-DEC-2025.

Details:
Pursuant to the Placing and Subscription Agreement, the Vendor undertakes to the Placing Agent that except for the sale of the Sale Shares pursuant to the Placing and Subscription Agreement for a period of 90 days from the Placing Closing Date.

Latest news about Simcere Pharmaceutical Group Limited

09:35am	Simcere Pharmaceutical to Spin Off, List Chinese Subsidiary; Shares Down 7%	MT
09/01	Simcere Pharmaceutical announces spin-off & separate listing of Simcere Zaiming Pharmaceutical	RE
23/12	Simcere Pharma Gets China Nod for Tumor Drug Trial	MT
23/12	Simcere Pharmaceutical says SIM0610 receives clinical trial approval from NMPA China	RE
23/12	Simcere Pharmaceutical Group Limited Receives Approval for Sim0610 by National Medical Products Administration of China	CI
22/12	Simcere Pharmaceutical enters exclusive licensing agreement with Ipsen	RE
22/12	Simcere Pharma Unit Signs Global Licensing Deal With Ipsen for Cancer Drug Candidate	MT
22/12	Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. Enters into an Exclusive Licensing Agreement with Ipsen Pharma Sas	CI
09/12	Certain Orinary Shares of Simcere Pharmaceutical Group Limited are subject to a Lock-Up Agreement Ending on 9-DEC-2025.	CI
08/12	China Adds Simcere's Enzeshu to National Reimbursement List, Endostar Secures Renewal	MT
08/12	Simcere Pharmaceutical Group Limited Announces the Inclusive of Enzeshu and Endostatin in the New National Reimbursement Drug List	CI
03/12	Vigonvita Life Sciences Co enters license agreement with Simcere for VV116	RE
03/12	Simcere pharmaceutical obtains exclusive rights for RSV and hMPV treatment	RE
03/12	Simcere Pharmaceutical Group Limited Enters into License Agreement with Vigonvita Life Science Co., Ltd	CI
02/12	Simcere Pharma Grants 15.4 million RSUs Under Incentive Scheme; Shares Slip 4%	MT
10/11	Simcere's IL-2 Mutant Fusion Protein Sim0278 Enters Phase II Clinical Trial Stage	CI
16/25/16	NextCure and Simcere Zaiming announce expansion of ongoing phase 1 trial of Sim0505 into the US	RE
08/25/08	Simcere Pharmaceutical Group says SIM0609 obtains clinical trial approval in China by NMPA	RE
08/25/08	Simcere Pharma Gets China Nod for Tumor Drug Trial	MT
08/25/08	Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by the National Medical Products Administration	CI
03/25/03	Simcere Pharmaceutical's Influenza Drug Application Accepted by Chinese Regulator	MT
03/25/03	Simcere pharmaceutical says NDA of Deunoxavir Marboxil accepted by China's NMPA	RE
03/25/03	Simcere Pharmaceutical Group Limited and Jiaxing AnDiCon Biotech Co., Ltd. Accepts New Drug Application of Deunoxavir Marboxil Granules	CI
02/25/02	Simcere Pharma to Raise Nearly HK$1.6 Billion via Share Placement, Top-Up Subscription	MT
02/25/02	Simcere Pharmaceutical to issue 121 million subscription shares	RE

Chart Simcere Pharmaceutical Group Limited

Duration

Period

Chart Simcere Pharmaceutical Group Limited

2096: Dynamic Chart

Company Profile

Simcere Pharmaceutical Group Ltd is a company engaged in research and development, production and sales of drugs. The Company's main products are generic drugs, including Bicun used for central nervous system diseases, Jepaso and Jiebaili used for oncology, as well as Yingtaiqing used for autoimmune diseases. The Company also produces various drugs, including Endostar used for oncology. The Company is also involved in providing promotion services for third-party drugs sold by medical institutions. The Company mainly conducts its businesses in the domestic market and overseas markets.

Employees

6,815

Sector

Pharmaceuticals

More about the company